Full Answer
How to buy Moderna shares?
Learn how to easily invest in Moderna stock.
- Moderna stock price (NASDAQ: MRNA) Use our graph to track the performance of MRNA stocks over time. Information last updated 2021-09-17.
- Buy Moderna shares from these brokerages. Compare special offers, low fees and a wide range of types of investments among top trading platforms.
- Shorting Moderna shares. ...
Is Moderna a good healthcare stock to buy now?
This is why Moderna is still one of the best stocks to buy now. If you’re not familiar, Moderna is one of the three companies to produce a COVID-19 vaccine. Even more impressively, it pioneered a completely new strategy for creating vaccines. The Moderna vaccine uses mRNA to instruct your cells on how to fight disease.
How much is Moderna really worth?
Today, after it developed and delivered one of the fastest-arriving and most effective shots against Covid-19, Moderna’s market value is approaching $100 billion. Some of the stock's 1,000% gain is undoubtedly warranted.
When will Moderna stock be a screaming buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Moderna (MRNA) reports results for the quarter ended December 2021.
Is Moderna a buy right now?
14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 1 sell rating, 8 h...
When is Moderna's next earnings date?
Moderna is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Moderna .
How were Moderna's earnings last quarter?
Moderna, Inc. (NASDAQ:MRNA) issued its earnings results on Wednesday, May, 4th. The company reported $8.58 earnings per share (EPS) for the quarter...
What price target have analysts set for MRNA?
14 Wall Street analysts have issued twelve-month target prices for Moderna's shares. Their forecasts range from $80.00 to $395.00. On average, they...
Who are Moderna's key executives?
Moderna's management team includes the following people: Dr. Noubar B. Afeyan Ph.D. , Co-Founder, Independent Non Exec. Chairman & Member of Tech...
What is Stéphane Bancel's approval rating as Moderna's CEO?
57 employees have rated Moderna CEO Stéphane Bancel on Glassdoor.com . Stéphane Bancel has an approval rating of 92% among Moderna's employees. Th...
Who are some of Moderna's key competitors?
Some companies that are related to Moderna include Amgen (AMGN) , Gilead Sciences (GILD) , BioNTech (BNTX) , Biogen (BIIB) , Seagen (SGEN) ,...
What other stocks do shareholders of Moderna own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA) , Tesla (TSLA...
When did Moderna IPO?
(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00...
Is Moderna stock a Buy, Sell or Hold?
Moderna stock has received a consensus rating of hold. The average rating score is and is based on 21 buy ratings, 27 hold ratings, and 8 sell rati...
What was the 52-week low for Moderna stock?
The low in the last 52 weeks of Moderna stock was 119.02. According to the current price, Moderna is 124.06% away from the 52-week low.
What was the 52-week high for Moderna stock?
The high in the last 52 weeks of Moderna stock was 497.00. According to the current price, Moderna is 29.71% away from the 52-week high.
What are analysts forecasts for Moderna stock?
The 56 analysts offering price forecasts for Moderna have a median target of 186.50, with a high estimate of 463.00 and a low estimate of 41.00. Th...
What is Moderna stock?
A Fundamental Look At Moderna Stock. The biotech company is banking on its messenger RNA, or mRNA, technology. Messenger RNA is a substance in the body that delivers the instructions for creating protein. The type of coronavirus that causes Covid-19 is covered in so-called spike proteins.
When did Moderna stock break out?
Moderna stock surged above a profit-taking zone after breaking out of a cup-with-handle base on June 30. Investors are encouraged to take profits when a stock is 20%-25% above its entry. As of midday trading on July 9, shares were about 23% above their buy point.
How much did Moderna make in the first quarter?
In the first quarter, Moderna earned $2.84 per share , minus some items, on $1.94 billion in revenue. The latter number included $1.73 billion in sales of its Covid vaccine. Profits beat forecasts, but sales lagged. The revenue growth was massive and profits are bullish, though it's still early innings.
What is the spike protein in Moderna?
The type of coronavirus that causes Covid-19 is covered in so-called spike proteins. Moderna's vaccine contains mRNA that tells the body to produce a structure similar to the spike protein. The idea is that this will trigger the immune system to create disease-fighting antibodies and T-cells.
How effective is Moderna?
At a final analysis, Moderna's Covid vaccin e was 94.1% effective. In March, the CDC said a test of health care workers in the U.S. showed Pfizer's and Moderna's vaccines are 80% effective after the first dose. The second dose increases the effectiveness to 90%.
How much will Moderna make in 2021?
Sales soared, but losses deepened. In 2021, analysts expect Moderna to earn $25.54 per share on $18.32 billion in sales. Earnings would swing from year-ago losses and sales would soar by a quadruple-digit percentage.
How long can Moderna be stored?
The FDA has said it would allow Moderna's vaccine to be stored for 24 hours at room temperature. A punctured vial is now considered usable for up to 12 hours, up from prior guidance for six hours. Workers can also get 15 doses from two vials, up from 11 previously.
NASDAQ: MRNA
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This company has been on a two-year winning streak
Moderna ( MRNA -0.42% ) has posted major gains for two straight years. In 2020, investors bet on the biotech company's ability to bring a coronavirus vaccine to market, and they won. Moderna scored Emergency Use Authorization and finished the year with a 434% share gain. This year, Moderna shares have advanced another 192%.
The story so far
First, let's catch up on the Moderna story. The biotech launched its vaccine about a year ago, shortly after that of bigger rival Pfizer, which has vaccinated the most Americans (although Moderna remains a close second). It's fair to say both are market leaders. Moderna predicts vaccine sales of $15 billion to $18 billion this year.
NASDAQ: MRNA
Investors rallied behind Moderna for most of this year. But some started to lose confidence in the stock's potential in recent months. As a result, shares slid 37% from a high reached in August. The problem? Investors worried Moderna's vaccine sales would slip as the pandemic eases -- and eventually drop significantly.
Advancing booster candidates
Right now, Moderna is moving forward with several strain-specific booster candidates. The most advanced are in phase 2 trials. And the company has even started the development of an omicron-specific candidate.
Buy, hold, or sell?
So, let's get back to our question. Should you buy, hold, or sell Moderna shares in 2022? Overall, I vote for buying or holding -- that's because there's so much more ahead for this innovative company. Next year and beyond.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What is Moderna based on?
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells. More at Wikipedia.
When will Moderna be available in 2021?
TOP PICK. Moderna (MRNA-Q) April 8, 2021. Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon.
What does a high score mean on Moderna?
Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
What is the symbol for Moderna?
What is Moderna stock symbol? Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q.
Is Moderna in phase 1?
Moderna is partnering with Swiss drugmaker, Lonza, to accelerate production on mRNA-1273, which was the first candidate to enter a phase 1 human trial back in March, though results are pending. A week ago, Moderna submitted an application to the FDA to start a phase 2 trial.
Is Moderna a biotech?
Moderna (MRNA-Q) March 15, 2021. A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.
How much did Moderna stock gain in 2021?
The Moderna Inc. stock price gained 0.0086% on the last trading day (Friday, 9th Jul 2021), rising from $232.79 to $232.81. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 4.24% from a day low at $224.28 to a day high of $233.80. The price has risen in 6 of the last 10 days and is up by 5.76% over the past 2 weeks. Volume fell on the last day by -3 million shares and in total, 5 million shares were bought and sold for approximately $1.23 billion. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
When is the sell signal for 2021?
A sell signal was issued from a pivot top point on Friday, July 23, 2021, and so far it has fallen -3.72%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Moderna stock is falling
On Nov. 4, Moderna stock fell by more than 16 percent after the drugmaker reduced its COVID-19 vaccine sales forecast for this year and missed its third-quarter earnings and sales expectations.
Should you sell Moderna stock now?
Moderna’s coronavirus vaccine is the company’s only commercialized product. The earnings announcement comes only two weeks after the FDA approved booster shots of Moderna's vaccine for tens of millions of Americans. Moderna estimates commercial booster market sales to reach $2 billion by 2022.
